SynBioBeta Speaker
Heather Courtney
Alwyn Capital
GP
Heather Courtney is the Founding General Partner of Alwyn Capital, an early-stage VC fund investing in biotechnology breakthroughs that are redefining trillion-dollar legacy industries to create a brighter, more efficient, future. Over the past eight years, Heather and the Alwyn Capital team have invested in companies at the forefront of transforming synthetic biology across protein innovation, next-generation materials, and advanced biological modeling.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Heather
This Year
•
-
Planetary Health
FoodTech Investing: Lessons Learned and the Road Ahead
The FoodTech sector has moved beyond its first wave of hype into a period of recalibration. Investors and founders alike are reassessing assumptions around cost, scale, and market adoption. In this closed-door luncheon, leading investors and industry operators will share hard-earned lessons from the past cycle and explore how those insights are shaping future investment strategies. From platform bets to capital-efficient models, the discussion will focus on what it takes to build durable FoodTech companies in today’s environment. Expect a candid focused on strategic clarity and actionable insight.
•
-
Planetary Health
FoodTech Investing: Lessons Learned and the Road Ahead
The FoodTech sector has moved beyond its first wave of hype into a period of recalibration. Investors and founders alike are reassessing assumptions around cost, scale, and market adoption. In this closed-door luncheon, leading investors and industry operators will share hard-earned lessons from the past cycle and explore how those insights are shaping future investment strategies. From platform bets to capital-efficient models, the discussion will focus on what it takes to build durable FoodTech companies in today’s environment. Expect a candid focused on strategic clarity and actionable insight.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
